Promacta Could Ease Hepatitis C Treatment Complications
Share
Follow Us
Glaxo’s Promacta May Turn Into Blockbuster Medicine, UBS Says
By Makiko Kitamura
Nov. 7 (Bloomberg) — GlaxoSmithKline Plc’s Promacta blood disorder medicine may generate as much as $2 billion in annual sales if the U.K.’s largest drugmaker can expand its use to the treatment of a condition associated with hepatitis C, according to UBS AG.
The medicine, already approved for sale in the U.S. to raise platelet counts in patients with a rare blood disorder, is being studied to extend use to patients with thrombocytopenia, a blood complication stemming from hepatitis C treatments. Glaxo will present results from the last of three stages of clinical testing required for regulatory approval on the new use at a medical meeting in San Francisco today.
Continue reading this entire article:
http://www.businessweek.com/news/2011-11-09/glaxo-s-promacta-may-turn-into-blockbuster-medicine-ubs-says.html
